← Evidence library

BIB_324

Schadendorf D et al. (Essen + multicentre). RELATIVITY-098: Adjuvant nivolumab plus relatlimab vs nivolumab alone in stage III/IV resected melanoma. Phase 3 randomized trial. Nat Med 2025. Establishes LAG-3 antibody in the adjuvant setting (parallel to the Stage IV opdualag approval). [Tasks: 17, 18, 19b] Tier: 1 (NM phase 3) Grade: A Retrieved: 2026-05-15

Evidence grade

A

Tier

1 (NM phase 3)

Cited by tasks

17, 18, 19b

Identifiers

DOI:10.1016/S1470-2045(25 · PMID:41109920

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_324/findings.md (research corpus). This page is a short context summary — not individualised medical advice.